Double-Blind, Four Week Trial Of [S,S]-Reboxetine And Atomoxetine In Adults With Attention Deficit Hyperactivity Disorder.

NCT00562055 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped This study was withdrawn due to business reasons.

Conditions

Attention Deficit Hyperactivity Disorder

Interventions

DRUG: Atomoxetine
DRUG: PNU-165442G; [S,S]-reboxetine

Sponsor

Pfizer